Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04647032
Recruitment Status : Recruiting
First Posted : November 30, 2020
Last Update Posted : March 16, 2021
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
The overall goal of this project is to improve cognitive control abilities in adults with mild cognitive impairment (MCI) through a form of non-invasive brain stimulation, transcranial alternating current stimulation (tACS).

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Device: Transcranial alternating current stimulation Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Enhancing Cognitive Control in Mild Cognitive Impairment Via Non-invasive Brain Stimulation
Actual Study Start Date : January 11, 2021
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Theta Stimulation Group
This group will receive 6 Hz (theta) stimulation
Device: Transcranial alternating current stimulation
Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4

Active Comparator: Delta Stimulation Group
This group will receive 1 Hz (delta) stimulation
Device: Transcranial alternating current stimulation
Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4




Primary Outcome Measures :
  1. Change in Divided Attention [ Time Frame: Pre-tACS (baseline), Post-tACS (1-day follow-up) ]
    Mean performance on a divided attention task will be compared pre and post intervention. Divided attention performance will be assessed on a tablet using the paradigm Endeavor that places simultaneous demands on sensory motor tracking and perceptual discrimination abilities.

  2. Change in Divided Attention [ Time Frame: Pre-tACS (baseline), Post-tACS (1-month follow-up) ]
    Mean performance on a divided attention task will be compared pre and post intervention. Divided attention performance will be assessed on a tablet using the paradigm Endeavor that places simultaneous demands on sensory motor tracking and perceptual discrimination abilities.

  3. Change in Sustained Attention [ Time Frame: Pre-tACS (baseline), Post-tACS (1-day follow-up) ]
    Mean performance on the sustained attention task will be compared pre and post intervention. Sustained attention performance will be assessed on a tablet using the paradigm TOVA that requires 1) responses to frequency targets (withhold infrequent) and 2) responses to infrequent targets (withhold frequent)

  4. Change in Sustained Attention [ Time Frame: Pre-tACS (baseline), Post-tACS (1-month follow-up) ]
    Mean performance on a sustained attention task will be compared pre and post intervention. Sustained attention performance will be assessed on a tablet using the paradigm TOVA that requires 1) responses to frequency targets (withhold infrequent) and 2) responses to infrequent targets (withhold frequent)

  5. Change in Working Memory [ Time Frame: Pre-tACS (baseline), Post-tACS (1-day follow-up) ]
    Mean performance on a working memory task will be compared pre and post intervention. Working memory performance will be assessed on a tablet using the paradigm ACE that characterizes working memory.

  6. Change in Working Memory [ Time Frame: Pre-tACS (baseline), Post-tACS (1-month follow-up) ]
    Mean performance on a working memory task will be compared pre and post intervention. Working memory performance will be assessed on a tablet using the paradigm ACE that characterizes working memory.


Secondary Outcome Measures :
  1. Change in Instrumental Activities of Daily Living (IADL) [ Time Frame: Pre-tACS (baseline), Post-tACS (1-day follow-up) ]
    Scores on the IADL will be assessed pre and post intervention. Higher scores are better (minimum = 0, maximum = 8).

  2. Change in Instrumental Activities of Daily Living (IADL) [ Time Frame: Pre-tACS (baseline), Post-tACS (1-month follow-up) ]
    Scores on the IADL will be assessed pre and post intervention. Higher scores are better (minimum = 0, maximum = 8).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • English speaking
  • Grade 12 or more education
  • Normal or corrected to normal vision and hearing
  • Ability to complete cognitive tasks
  • Ability to cooperate and comply with all study procedures
  • Ability to tolerate tACS
  • Montreal Cognitive Assessment score: 17-28
  • -1 z-score on immediate memory, delayed memory, fluency, processing speed, or task switch
  • Self-reported memory complaint

Exclusion Criteria:

  • Neurological or psychiatric disorders other than mild cognitive impairment
  • Receiving investigational medications or have participated in a trial with investigational medications within last 30 days
  • Family history of epilepsy
  • Implanted electronic devices (e.g., pacemaker)
  • Prior head trauma
  • Pregnant
  • IQ < 80
  • Taking cholinesterase inhibitory, memantine, or psychotropic medication
  • Taking anti-depressants or anti-anxiety medication
  • Color blind
  • Substance abuse
  • Glaucoma
  • Macular degeneration
  • Amblyopia (lazy eye)
  • Strabismus (crossed eyes)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04647032


Contacts
Layout table for location contacts
Contact: Theodore Zanto, Ph.D. 415-364-8209 theodore.zanto@ucsf.edu
Contact: Avery Ostrand, B.S. 415-364-8209 avery.ostrand@ucsf.edu

Locations
Layout table for location information
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94158
Contact: Avery Ostrand, B.S.    415-364-8209    avery.ostrand@ucsf.edu   
Sponsors and Collaborators
University of California, San Francisco
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Theodore Zanto, Ph.D. University of California, San Francisco
Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04647032    
Other Study ID Numbers: 132026a
R21AG062395 ( U.S. NIH Grant/Contract )
First Posted: November 30, 2020    Key Record Dates
Last Update Posted: March 16, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized IPD will be made available in accordance with NIH guidelines and IRB approval.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders